File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

TitlePreliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Authors
Garcia-Manero, GuillermoAbaza, YasminGreenberg, Peter LHaque, TamannaVelázquez, Kennedy KyraDella, Porta Matteo GiovanniOoi, Melissa GStahl, MaximilianXie, ZhuoerMangaonkar, Abhishek ADesai, PinkalDeZern, Amy EGarnier, AliceMeunier, MathieuPelizzari, Anna MariaPlatzbecker, UweSockel, KatjaKishtagari, AshwinLu, HongboManganelli, LucaJi, LexiangYan, ZhengLi, YutongRoy, MikeGatlik, EwaSingh, ArtiBeaulieu, ValeriePelletier, MarcRauch, PhilippGill, Harinder
Issue Date5-Nov-2024
PublisherAmerican Society of Hematology (ASH Publications)
Citation
Blood, 2024, v. 144, n. Suppl 1 How to Cite?
DOI: http://dx.doi.org/10.1182/blood-2024-198326
Persistent Identifierhttp://hdl.handle.net/10722/354087
ISSN
0006-4971
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272

 

DC FieldValueLanguage
dc.contributor.authorGarcia-Manero, Guillermo-
dc.contributor.authorAbaza, Yasmin-
dc.contributor.authorGreenberg, Peter L-
dc.contributor.authorHaque, Tamanna-
dc.contributor.authorVelázquez, Kennedy Kyra-
dc.contributor.authorDella, Porta Matteo Giovanni-
dc.contributor.authorOoi, Melissa G-
dc.contributor.authorStahl, Maximilian-
dc.contributor.authorXie, Zhuoer-
dc.contributor.authorMangaonkar, Abhishek A-
dc.contributor.authorDesai, Pinkal-
dc.contributor.authorDeZern, Amy E-
dc.contributor.authorGarnier, Alice-
dc.contributor.authorMeunier, Mathieu-
dc.contributor.authorPelizzari, Anna Maria-
dc.contributor.authorPlatzbecker, Uwe-
dc.contributor.authorSockel, Katja-
dc.contributor.authorKishtagari, Ashwin-
dc.contributor.authorLu, Hongbo-
dc.contributor.authorManganelli, Luca-
dc.contributor.authorJi, Lexiang-
dc.contributor.authorYan, Zheng-
dc.contributor.authorLi, Yutong-
dc.contributor.authorRoy, Mike-
dc.contributor.authorGatlik, Ewa-
dc.contributor.authorSingh, Arti-
dc.contributor.authorBeaulieu, Valerie-
dc.contributor.authorPelletier, Marc-
dc.contributor.authorRauch, Philipp-
dc.contributor.authorGill, Harinder-
dc.date.accessioned2025-02-07T00:35:34Z-
dc.date.available2025-02-07T00:35:34Z-
dc.date.issued2024-11-05-
dc.identifier.citationBlood, 2024, v. 144, n. Suppl 1-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/354087-
dc.languageeng-
dc.publisherAmerican Society of Hematology (ASH Publications)-
dc.relation.ispartofBlood-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePreliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study-
dc.typeArticle-
dc.identifier.doi10.1182/blood-2024-198326-
dc.identifier.volume144-
dc.identifier.issueSuppl 1-
dc.identifier.eissn1528-0020-
dc.identifier.issnl0006-4971-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats